How can the risk that orphan drugs present to budgets be managed better?
- PMID: 20974321
- DOI: 10.1016/j.clinthera.2010.08.007
How can the risk that orphan drugs present to budgets be managed better?
Comment on
-
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006. Clin Ther. 2010. PMID: 20974323
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical